You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for pep2m
Peptide inhibitor of the interaction between the C-terminus of the GluA2 (AMPA receptor) subunit and N-ethylmaleimide-sensitive fusion protein (NSF), a protein that regulates AMPA receptor function. Reduces postsynaptic currents in CA1 neurons, AMPA-mediated currents in cultured hippocampal neurons and AMPA receptor surface expression.
Control Peptide also available.
Technical Data for pep2m
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References for pep2m
References are publications that support the biological activity of the product.
Collingridge and Isaac (2003) Functional roles of protein interactions with AMPA and kainate receptors. Neurosci.Res. 47 3 PMID: 12941441
Luscher et al (1999) Role of AMPA receptor cycling in synaptic transmission and plasticity. Neuron 24 649 PMID: 10595516
Luthi et al (1999) Hippocampal LTD expression involves a pool of AMPARs regulated by the NSF-GluR2 interaction. Neuron 24 389 PMID: 10571232
Nishimune et al (1998) NSF binding to GluR2 regulates synaptic transmission. Neuron 21 87 PMID: 9697854
Noel et al (1999) Surface expression of AMPA receptors in hippocampal neurons is regulated by an NSF-dependent mechanism. Neuron 23 365 PMID: 10399941
View Related Products by Product Action
Keywords: pep2m, pep2m supplier, Peptide, inhibitors, inhibits, GluR2, subunit, binding, NSF, N-ethylmaleimide-sensitive, fusion, protein, Reduces, AMPA, currents, Glutamate, Receptors, iGlur, Ionotropic, GluA2, GluR2m, G10, 1595, Tocris Bioscience
1 Citation for pep2m
Citations are publications that use Tocris products. Selected citations for pep2m include:
Yao et al (2008) PKM ζ maintains late long-term potentiation by N-ethylmaleimide-sensitive factor/GluR2-dependent trafficking of postsynaptic AMPA receptors. Proc Natl Acad Sci U S A 28 7820 PMID: 18667614
Reviews for pep2m
There are currently no reviews for this product. Be the first to review pep2m and earn rewards!
Have you used pep2m?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.